GlobalData on MSN5d
Positive Phase III results for linerixibat in cholestatic pruritus treatment for PBC patientsPBC patients receiving linerixibat saw statistically significant improvement in cholestatic pruritus - or relentless itch.
A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...
Zacks.com on MSN5d
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III StudyGSK plc GSK announced positive headline data from the phase III GLISTEN study, which is evaluating its investigational ...
UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...
GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its ...
Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...
GSK (GSK) announced headline results of GLISTEN, the ongoing global phase III clinical trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter, IBAT, in ...
Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...
GSK has announced positive headline results of its ongoing global Phase III clinical trial GLISTEN, which is evaluating the use of linerixibat in the treatment of adult patients with cholestatic ...
Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) · Primary endpoint met with a statistically significant improvement in ...
(Alliance News) - GSK PLC on Tuesday said that its investigational targeted inhibitor linerixibat demonstrated sound results for a treatment of relentless itch. The London-based pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback